Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma

Journal of Hepatology

Volumn 48, Issue 1, 2008, Pages 163-170

  Rebouissou, Sandra ^a,b   Bioulac Sage, Paulette ^a,c   Zucman Rossi, Jessica ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

Catenin; Benign tumor; Chromosome; CRP; Estrogen; FABP1; Focal nodular hyperplasia; Gene mutation; Genetic alteration; Hepatocellular adenoma; Hepatocyte nuclear factor 1; Inflammation; SAA; Steatosis

Indexed keywords

BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 1;

CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CORRELATION ANALYSIS; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; LIVER ADENOMA; LIVER BLOOD FLOW; LIVER CELL; NODULAR HYPERPLASIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ADENOMA, LIVER CELL; FOCAL NODULAR HYPERPLASIA; HUMANS; LIVER NEOPLASMS; MUTATION;

EID: 36749011267     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.10.003     Document Type: Review

References (110)

1. Edmondson H.A. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology (1958), Armed Forces Institute of Pathology, Washington (DC)
2. Nguyen B.N., Flejou J.F., Terris B., Belghiti J., and Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 23 (1999) 1441-1454
3. Heinemann L.A., Weimann A., Gerken G., Thiel C., Schlaud M., and DoMinh T. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur J Contracept Reprod Health Care 3 (1998) 194-200
4. Mathieu D., Kobeiter H., Cherqui D., Rahmouni A., and Dhumeaux D. Oral contraceptive intake in women with focal nodular hyperplasia of the liver. Lancet 352 (1998) 1679-1680
5. Scalori A., Tavani A., Gallus S., La Vecchia C., and Colombo M. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 186 (2002) 195-197
6. Wanless I.R., Mawdsley C., and Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 5 (1985) 1194-1200
7. Altavilla G., and Guariso G. Focal nodular hyperplasia of the liver associated with portal vein agenesis: a morphological and immunohistochemical study of one case and review of the literature. Adv Clin Path 3 (1999) 139-145
8. Buscarini E., Danesino C., Plauchu H., de Fazio C., Olivieri C., Brambilla G., et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 30 (2004) 1089-1097
9. De Gaetano A.M., Gui B., Macis G., Manfredi R., and Di Stasi C. Congenital absence of the portal vein associated with focal nodular hyperplasia in the liver in an adult woman: imaging and review of the literature. Abdom Imaging 29 (2004) 455-459
10. Makhlouf H.R., Abdul-Al H.M., and Goodman Z.D. Diagnosis of focal nodular hyperplasia of the liver by needle biopsy. Hum Pathol 36 (2005) 1210-1216
11. Bioulac-Sage P., Balabaud C., Bedossa P., Scoazec J.Y., Chiche L., Dhillon A.P., et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 46 (2007) 521-527
12. Fukukura Y., Nakashima O., Kusaba A., Kage M., and Kojiro M. Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. J Hepatol 29 (1998) 470-475
13. Gaiani S., Piscaglia F., Serra C., and Bolondi L. Hemodynamics in focal nodular hyperplasia. J Hepatol 31 (1999) 576
14. Wanless I.R., Albrecht S., Bilbao J., Frei J.V., Heathcote E.J., Roberts E.A., et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol 2 (1989) 456-462
15. Gaffey M.J., Iezzoni J.C., and Weiss L.M. Clonal analysis of focal nodular hyperplasia of the liver. Am J Pathol 148 (1996) 1089-1096
16. Chen T.C., Chou T.B., Ng K.F., Hsieh L.L., and Chou Y.H. Hepatocellular carcinoma associated with focal nodular hyperplasia. Report of a case with clonal analysis. Virchows Arch 438 (2001) 408-411
17. Zhang S.H., Cong W.M., and Wu M.C. Focal nodular hyperplasia with concomitant hepatocellular carcinoma: a case report and clonal analysis. J Clin Pathol 57 (2004) 556-559
18. Paradis V., Laurent A., Flejou J.F., Vidaud M., and Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 26 (1997) 891-895
19. Bioulac-Sage P., Rebouissou S., Sa Cunha A., Jeannot E., Lepreux S., Blanc J.F., et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 128 (2005) 1211-1218
20. Raidl M., Pirker C., Schulte-Hermann R., Aubele M., Kandioler-Eckersberger D., Wrba F., et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol 40 (2004) 660-668
21. Kellner U., Jacobsen A., Kellner A., Mantke R., Roessner A., and Rocken C. Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations. Am J Clin Pathol 119 (2003) 265-271
22. Heimann P., Ogur G., Debusscher C., De Valck C., Sariban E., Deprez C., et al. Multiple clonal chromosome aberrations in a case of childhood focal nodular hyperplasia of the liver. Cancer Genet Cytogenet 85 (1995) 138-142
23. Chen Y.J., Chen P.J., Lee M.C., Yeh S.H., Hsu M.T., and Lin C.H. Chromosomal analysis of hepatic adenoma and focal nodular hyperplasia by comparative genomic hybridization. Genes Chromosomes Cancer 35 (2002) 138-143
24. Chen Y.W., Jeng Y.M., Yeh S.H., and Chen P.J. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 36 (2002) 927-935
25. Blaker H., Sutter C., Kadmon M., Otto H.F., Von Knebel-Doeberitz M., Gebert J., et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer 41 (2004) 93-98
26. Scoazec J.Y., Flejou J.F., D'Errico A., Couvelard A., Kozyraki R., Fiorentino M., et al. Focal nodular hyperplasia of the liver: composition of the extracellular matrix and expression of cell-cell and cell-matrix adhesion molecules. Hum Pathol 26 (1995) 1114-1125
27. Baum J.K., Bookstein J.J., Holtz F., and Klein E.W. Possible association between benign hepatomas and oral contraceptives. Lancet 2 (1973) 926-929
28. Edmondson H.A., Henderson B., and Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 294 (1976) 470-472
29. Lansing P.B., McQuitty J.T., and Bradburn D.M. Benign liver tumors: what is their relationship to oral contraceptives?. Am Surg 42 (1976) 744-760
30. Vana J., Murphy G.P., Aronoff B.L., and Baker H.W. Primary liver tumors and oral contraceptives. Results of a survey. Jama 238 (1977) 2154-2158
31. Christopherson W.M., Mays E.T., and Barrows G. A clinicopathologic study of steroid-related liver tumors. Am J Surg Pathol 1 (1977) 31-41
32. Rooks J.B., Ory H.W., Ishak K.G., Strauss L.T., Greenspan J.R., Hill A.P., et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. Jama 242 (1979) 644-648
33. Farrell G.C., Joshua D.E., Uren R.F., Baird P.J., Perkins K.W., and Kronenberg H. Androgen-induced hepatoma. Lancet 1 (1975) 430-432
34. Lesna M., Spencer I., and Walker W. Letter: liver nodules and androgens. Lancet 1 (1976) 1124
35. Sale G.E., and Lerner K.G. Multiple tumors after androgen therapy. Arch Pathol Lab Med 101 (1977) 600-603
36. Johnson F.L., Lerner K.G., Siegel M., Feagler J.R., Majerus P.W., Hartmann J.R., et al. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 2 (1972) 1273-1276
37. Henderson J.T., Richmond J., and Sumerling M.D. Androgenic-anabolic steroid therapy and hepatocellular carcinoma. Lancet 1 (1973) 934
38. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152 (1993) S63-S70
39. Lee P., Mather S., Owens C., Leonard J., and Dicks-Mireaux C. Hepatic ultrasound findings in the glycogen storage diseases. Br J Radiol 67 (1994) 1062-1066
40. Smit G.P., Fernandes J., Leonard J.V., Matthews E.E., Moses S.W., Odievre M., et al. The long-term outcome of patients with glycogen storage diseases. J Inherit Metab Dis 13 (1990) 411-418
41. de Parscau L., Guibaud P., and Maire I. Glycogenoses type 1b and 1c. Pediatrie 43 (1988) 661-665
42. Talente G.M., Coleman R.A., Alter C., Baker L., Brown B.I., Cannon R.A., et al. Glycogen storage disease in adults. Ann Intern Med 120 (1994) 218-226
43. Labrune P., Trioche P., Duvaltier I., Chevalier P., and Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 24 (1997) 276-279
44. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983-993.
45. Flejou J.F., Barge J., Menu Y., Degott C., Bismuth H., Potet F., et al. Liver adenomatosis. An entity distinct from liver adenoma?. Gastroenterology 89 (1985) 1132-1138
46. Chiche L., Dao T., Salame E., Galais M.P., Bouvard N., Schmutz G., et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg 231 (2000) 74-81
47. Grazioli L., Federle M.P., Ichikawa T., Balzano E., Nalesnik M., and Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 216 (2000) 395-402
48. Foster J.H., Donohue T.A., and Berman M.M. Familial liver-cell adenomas and diabetes mellitus. N Engl J Med 299 (1978) 239-241
49. Buhler H., Pirovino M., Akobiantz A., Altorfer J., Weitzel M., Maranta E., et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 82 (1982) 775-782
50. Steinbrecher U.P., Lisbona R., Huang S.N., and Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 26 (1981) 1045-1050
51. Mariani A.F., Livingstone A.S., Pereiras Jr. R.V., van Zuiden P.E., and Schiff E.R. Progressive enlargement of an hepatic cell adenoma. Gastroenterology 77 (1979) 1319-1325
52. Svrcek M., Jeannot E., Arrive L., Poupon R., Fromont G., Flejou J.F., et al. Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur J Endocrinol 156 (2007) 617-621
53. Westaby D., Portmann B., and Williams R. Androgen related primary hepatic tumors in non-Fanconi patients. Cancer 51 (1983) 1947-1952
54. Touraine R.L., Bertrand Y., Foray P., Gilly J., and Philippe N. Hepatic tumours during androgen therapy in Fanconi anaemia. Eur J Pediatr 152 (1993) 691-693
55. Socas L., Zumbado M., Perez-Luzardo O., Ramos A., Perez C., Hernandez J.R., et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 39 (2005) e27
56. Parker P., Burr I., Slonim A., Ghishan F.K., and Greene H. Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. Gastroenterology 81 (1981) 534-536
57. Kerlin P., Davis G.L., McGill D.B., Weiland L.H., Adson M.A., and Sheedy II P.F. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 84 (1983) 994-1002
58. Kent D.R., Nissen E.D., Nissen S.E., and Ziehm D.J. Effect of pregnancy on liver tumor associated with oral contraceptives. Obstet Gynecol 51 (1978) 148-151
59. Foster J.H., and Berman M.M. The malignant transformation of liver cell adenomas. Arch Surg 129 (1994) 712-717
60. Grigsby P., Meyer J.S., Sicard G.A., Huggins M.B., Lamar D.J., and DeSchryver-Kecskemeti K. Hepatic adenoma within a spindle cell carcinoma in a woman with a long history of oral contraceptives. J Surg Oncol 35 (1987) 173-179
61. Gyorffy E.J., Bredfeldt J.E., and Black W.C. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 110 (1989) 489-490
62. Korula J., Yellin A., Kanel G., Campofiori G., and Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J Med 155 (1991) 416-418
63. Tao L.C. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 68 (1991) 341-347
64. Conti J.A., and Kemeny N. Type Ia glycogenosis associated with hepatocellular carcinoma. Cancer 69 (1992) 1320-1322
65. Franco L.M., Krishnamurthy V., Bali D., Weinstein D.A., Arn P., Clary B., et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 28 (2005) 153-162
66. Gong L., Su Q., Zhang W., Li A.N., Zhu S.J., and Feng Y.M. Liver cell adenoma: a case report with clonal analysis and literature review. World J Gastroenterol 12 (2006) 2125-2129
67. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 25 (2006) 3778-3786
68. Wilkens L., Bredt M., Flemming P., Becker T., Klempnauer J., and Kreipe H.H. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol 193 (2001) 476-482
69. Nasarek A., Werner M., Nolte M., Klempnauer J., and Georgii A. Trisomy 1 and 8 occur frequently in hepatocellular carcinoma but not in liver cell adenoma and focal nodular hyperplasia. A fluorescence in situ hybridization study. Virchows Arch 427 (1995) 373-378
70. Wilkens L., Bredt M., Flemming P., Schwarze Y., Becker T., Mengel M., et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 3 (2001) 68-73
71. De Souza A.T., Hankins G.R., Washington M.K., Fine R.L., Orton T.C., and Jirtle R.L. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10 (1995) 1725-1729
72. Tannapfel A., Busse C., Geissler F., Witzigmann H., Hauss J., and Wittekind C. INK4a-ARF alterations in liver cell adenoma. Gut 51 (2002) 253-258
73. Bach I., Galcheva-Gargova Z., Mattei M.G., Simon-Chazottes D., Guenet J.L., Cereghini S., et al. Cloning of human hepatic nuclear factor 1 (HNF1) and chromosomal localization of its gene in man and mouse. Genomics 8 (1990) 155-164
74. Courtois G., Morgan J.G., Campbell L.A., Fourel G., and Crabtree G.R. Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science 238 (1987) 688-692
75. Pontoglio M., Barra J., Hadchouel M., Doyen A., Kress C., Bach J.P., et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84 (1996) 575-585
76. Lee Y.H., Sauer B., and Gonzalez F.J. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse. Mol Cell Biol 18 (1998) 3059-3068
77. Shih D.Q., Bussen M., Sehayek E., Ananthanarayanan M., Shneider B.L., Suchy F.J., et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 27 (2001) 375-382
78. Shih D.Q., Screenan S., Munoz K.N., Philipson L., Pontoglio M., Yaniv M., et al. Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes 50 (2001) 2472-2480
79. Akiyama T.E., Ward J.M., and Gonzalez F.J. Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice. J Biol Chem 275 (2000) 27117-27122
80. Bluteau O., Jeannot E., Bioulac-Sage P., Marques J.M., Blanc J.F., Bui H., et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 32 (2002) 312-315
81. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43 (2006) 515-524
82. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J.F., Sa Cunha A., Rullier A., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46 (2007) 740-748
83. Laurent-Puig P., Plomteux O., Bluteau O., Zinzindohoue F., Jeannot E., Dahan K., et al. Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. Gastroenterology 124 (2003) 1311-1314
84. Rebouissou S., Rosty C., Lecuru F., Boisselier S., Bui H., Le Frere-Belfa M.A., et al. Mutation of TCF1 encoding hepatocyte nuclear factor 1alpha in gynecological cancer. Oncogene 23 (2004) 7588-7592
85. Rebouissou S., Vasiliu V., Thomas C., Bellanne-Chantelot C., Bui H., Chretien Y., et al. Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet 14 (2005) 603-614
86. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
87. Rebouissou S., Imbeaud S., Balabaud C., Boulanger V., Bertrand-Michel J., Terce F., et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem 282 (2007) 14437-14446
88. Miyoshi Y., Iwao K., Nagasawa Y., Aihara T., Sasaki Y., Imaoka S., et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58 (1998) 2524-2527
89. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95 (1998) 8847-8851
90. Nagafuchi A., and Takeichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1 (1989) 37-44
91. Micsenyi A., Tan X., Sneddon T., Luo J.H., Michalopoulos G.K., and Monga S.P. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 126 (2004) 1134-1146
92. Suksaweang S., Lin C.M., Jiang T.X., Hughes M.W., Widelitz R.B., and Chuong C.M. Morphogenesis of chicken liver: identification of localized growth zones and the role of beta-catenin/Wnt in size regulation. Dev Biol 266 (2004) 109-122
93. Monga S.P., Monga H.K., Tan X., Mule K., Pediaditakis P., and Michalopoulos G.K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 124 (2003) 202-216
94. Benhamouche S., Decaens T., Godard C., Chambrey R., Rickman D.S., Moinard C., et al. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell 10 (2006) 759-770
95. Cadoret A., Ovejero C., Terris B., Souil E., Levy L., Lamers W.H., et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21 (2002) 8293-8301
96. Monga S.P., Pediaditakis P., Mule K., Stolz D.B., and Michalopoulos G.K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 33 (2001) 1098-1109
97. Tan X., Behari J., Cieply B., Michalopoulos G.K., and Monga S.P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131 (2006) 1561-1572
98. Takayasu H., Motoi T., Kanamori Y., Kitano Y., Nakanishi H., Tange T., et al. Two case reports of childhood liver cell adenomas harboring beta-catenin abnormalities. Hum Pathol 33 (2002) 852-855
99. Torbenson M., Lee J.H., Choti M., Gage W., Abraham S.C., Montgomery E., et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol 15 (2002) 189-196
100. Lehmann U., Berg-Ribbe I., Wingen L.U., Brakensiek K., Becker T., Klempnauer J., et al. Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 11 (2005) 3654-3660
101. Vander Borght S., Libbrecht L., Blokzijl H., Faber K.N., Moshage H., Aerts R., et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 207 (2005) 471-482
102. Sa Cunha A., Blanc J.F., Lazaro E., Mellottee L., Le Bail B., Zucman-Rossi J., et al. Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management. Gut 56 (2007) 307-309
103. Yamagata K., Oda N., Kaisaki P.J., Menzel S., Furuta H., Vaxillaire M., et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384 (1996) 455-458
104. Bacq Y., Jacquemin E., Balabaud C., Jeannot E., Scotto B., Branchereau S., et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 125 (2003) 1470-1475
105. Reznik Y., Dao T., Coutant R., Chiche L., Jeannot E., Clauin S., et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab 89 (2004) 1476-1480
106. Chen P.J. Genetic mutation in hepatic adenoma: seeing is believing. J Hepatol 45 (2006) 767-769
107. Jeannot E., Poussin K., Chiche L., Bacq Y., Sturm N., Scoazec J.Y., et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res 67 (2007) 2611-2616
108. Joslyn G., Carlson M., Thliveris A., Albertsen H., Gelbert L., Samowitz W., et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 66 (1991) 601-613
109. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 (1991) 589-600
110. Bala S., Wunsch P.H., and Ballhausen W.G. Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. Gastroenterology 112 (1997) 919-922